Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of intravitreal Lucentis for macular edema due to central retinal vein occlusion
2008-007175-24Phase 2Completed
- Sponsor
- University of Pécs
- Start
- Jan 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in central retinal vein occlusion with macular edema and central retinal vein occlusion (CRVO) (2 arms), sponsored by University of Pécs. Primary endpoint: Mean change in best-corrected visual acuity. Started Jan 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion with macular edemacentral retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2008-007175-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007175-24.